Certara, Inc. (NASDAQ:CERT) Shares Acquired by Daventry Group LP

Daventry Group LP grew its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,642,053 shares of the company's stock after buying an additional 127,954 shares during the period. Certara makes up 6.7% of Daventry Group LP's portfolio, making the stock its 9th biggest position. Daventry Group LP owned approximately 1.02% of Certara worth $17,488,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of CERT. Venturi Wealth Management LLC lifted its holdings in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Certara in the fourth quarter valued at approximately $47,000. Blue Trust Inc. increased its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd raised its holdings in shares of Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after acquiring an additional 3,656 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Stock Performance

NASDAQ CERT opened at $11.37 on Wednesday. The firm has a market capitalization of $1.84 billion, a P/E ratio of -56.85, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm's fifty day moving average price is $11.68 and its two-hundred day moving average price is $11.66. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.81.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on CERT. Robert W. Baird increased their target price on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. KeyCorp lifted their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. William Blair reaffirmed a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. TD Cowen initiated coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective on the stock. Finally, Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.17.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.